NAMPT and neoplasm: One of the major obstacles to the clinical progress involving the first generation NAMPT inhibitors, FK866 and CHS828, was the occurrence of off-tumor toxicities, primarily thrombocytopenia and gastrointestinal symptoms 41-43.